Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma

Vera Himmelsbach1 · Mate Knabe1 · Phillip G. Ferstl1 · Kai-Henrik Peiffer1 · Jan A. Stratmann4,5 · Thomas A. Wichelhaus2,3 · Michael Hogardt2,3 · Volkhard A. J. Kempf2,3 · Stefan Zeuzem1 · Oliver Waidmann1,4 · Fabian Finkelmeier1,4 · Olivier Ballo1,4,5

Received: 3 May 2021 / Accepted: 12 July 2021 / Published online: 20 July 2021
© The Author(s) 2021

Abstract
Introduction MDRO-colonization has been shown to impair survival in patients with hematological malignancies and solid tumors as well as in patients with liver disease. Despite the increasing spread of multidrug-resistant organisms (MDRO), its impact on patients with hepatocellular carcinoma (HCC) has not been studied. We conducted this retrospective study to analyze the impact of MDRO-colonization on overall prognosis in HCC patients.

Materials and methods All patients with confirmed HCC diagnosed between January 2008 and December 2017 at the University Hospital Frankfurt were included in this study. HCC patients with a positive MDRO screening before or within the first 90 days after diagnosis of HCC were defined as colonized HCC patients, HCC patients with a negative MDRO screening were defined as noncolonized HCC patients.

Results 59 (6%) colonized and 895 (94%) noncolonized HCC patients were included. Enterobacterales with extended-spectrum β-lactamase-like phenotype with or without resistance to fluoroquinolones (ESBL/±FQ) were the most frequently found MDRO with 59%, followed by vancomycin-resistant Enterococcus faecium with 37%. Colonized HCC patients had more severe cirrhosis and more advanced HCC stage compared to noncolonized HCC patients. Colonized HCC patients showed an impaired survival with a median OS of 189 days (6.3 months) compared to a median OS of 1001 days (33.4 months) in noncolonized HCC patients. MDRO-colonization was identified as an independent risk factor associated with survival in multivariate analysis.

Conclusion MDRO-colonization is an independent risk factor for survival in patients with HCC highlighting the importance of regular MDRO screening, isolation measures as well as interdisciplinary antibiotic steward-ship programs to guide responsible use of antibiotic agents.

Keywords Hepatocellular carcinoma · Multidrug-resistant organisms · Infection · Antibiotic steward-ship · Antibiotics · ESBL · VRE · Survival · Liver cancer

Abbreviations

| Acronym | Description                  |
|---------|------------------------------|
| AFP     | Alpha-fetoprotein            |
| ALBI    | Albumin–Bilirubin            |
| BCLC    | Barcelona clinic liver cancer|
| CI      | Confidence interval          |
| CPS     | Child–Pugh stage             |
| CR      | Complete response            |
| CRE     | Carbenem-resistant Enterobacterales|
| CT      | Computed tomography          |
| ESBL/±FQ| Enterobacterales With extended-spectrum β-lactamase-like phenotype with or without resistance to fluoroquinolones|
| HCC     | Hepatocellular carcinoma     |
| MDRO    | Multidrug-resistant organisms|
VRE  Vancomycin-resistant
TACE  Transarterial chemoembolization
OS  Overall survival
NASH  Non-alcoholic steatohepatitis

Apart from the cancer disease itself, first line treatment for these patients (Finn et al. 2020). The combined treatment of atezolizumab and bevacizumab has become the favored regimen in the past decade. In 2020 immunotherapy with the combination of pembrolizumab and nivolumab has become the favored treatment in patients with established cirrhosis (European Association for the Study of the Liver 2018). Curative HCC treatment with local ablative procedures, surgical resection or liver transplantation is reserved for patients in early stages with sufficient liver function (European Association for the Study of the Liver 2018). For HCC patients with unresectable advanced stages palliative treatment with transarterial chemoembolization (TACE) or sorafenib has been standard of care in the past decade. In 2020 immunotherapy with the combination of atezolizumab and bevacizumab has become the favored first line treatment for these patients (Finn et al. 2020).

The global spread of multidrug-resistant organisms (MDRO), namely, vancomycin-resistant Enterococcus faecalis/faeceum (VRE), methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Gram-negative bacteria (MDRGN) complicates treatment and isolation measures in health care (2013). MDRO-colonization has been shown to especially impair survival in patients with hematological malignancies and solid tumors as well as in patients with liver disease (Ballo et al. 2019; Ferstl et al. 2017, 2021; Stratmann et al. 2020; Arvaniti et al. 2010; Waidmann et al. 2015). Apart from the cancer disease itself, most HCC patients also suffer from relevant chronic liver disease. Infectious complications, mostly by bacteria belong to the predominant causes of acute on chronic liver failure leading to high rates of death (Waidmann et al. 2015; Ferstl et al. 2021). As MDRO severely narrow antibiotic treatment options higher mortality rates in patients with liver disease and MDRO are reported (Waidmann et al. 2015; Ferstl et al. 2021; Fernandez et al. 2016a). Despite the knowledge of MDRO-colonization adversely affecting survival in these patients, no studies are available investigating the impact of MDRO-colonization in patients with HCC. Considering that many HCC patients do not die due to uncontrolled tumor growth but due to complications of cirrhosis (e.g., sepsis) there is a need to improve supportive measures, e.g., by avoiding MDRO-colonization and lethal infections (Couto et al. 2007).

We conducted this retrospective analysis to determine the incidence of MDRO-colonization in HCC patients and to evaluate its impact on the clinical course.

Introduction

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally and the most common malignant primary liver cancer disease. HCC usually develops as a result of chronic liver disease due to chronic viral hepatitis, alcohol abuse and in fast increasing numbers from non-alcoholic steatohepatitis (nASH). The risk of HCC development increases with the stage of liver fibrosis. The cumulative risk for HCC development in patients with established cirrhosis ranges from 5 to 30% within 5 years (Villanueva 2019). HCC treatment is performed according to the BCLC (Barcelona Clinic Liver Cancer) stages (European Association for the Study of the Liver 2018). Curative HCC treatment with local ablative procedures, surgical resection or liver transplantation is reserved for patients in early stages with sufficient liver function (European Association for the Study of the Liver 2018). For HCC patients with unresectable advanced stages palliative treatment with transarterial chemoembolization (TACE) or sorafenib has been standard of care in the past decade. In 2020 immunotherapy with the combination of atezolizumab and bevacizumab has become the favored first line treatment for these patients (Finn et al. 2020).

The global spread of multidrug-resistant organisms (MDRO), namely, vancomycin-resistant Enterococcus faecalis/faeceum (VRE), methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Gram-negative bacteria (MDRGN) complicates treatment and isolation measures in health care (2013). MDRO-colonization has been shown to especially impair survival in patients with hematological malignancies and solid tumors as well as in patients with liver disease (Ballo et al. 2019; Ferstl et al. 2017, 2021; Stratmann et al. 2020; Arvaniti et al. 2010; Waidmann et al. 2015). Apart from the cancer disease itself, most HCC patients also suffer from relevant chronic liver disease. Infectious complications, mostly by bacteria belong to the predominant causes of acute on chronic liver failure leading to high rates of death (Waidmann et al. 2015; Ferstl et al. 2021). As MDRO severely narrow antibiotic treatment options higher mortality rates in patients with liver disease and MDRO are reported (Waidmann et al. 2015; Ferstl et al. 2021; Fernandez et al. 2016a). Despite the knowledge of MDRO-colonization adversely affecting survival in these patients, no studies are available investigating the impact of MDRO-colonization in patients with HCC. Considering that many HCC patients do not die due to uncontrolled tumor growth but due to complications of cirrhosis (e.g., sepsis) there is a need to improve supportive measures, e.g., by avoiding MDRO-colonization and lethal infections (Couto et al. 2007).

We conducted this retrospective analysis to determine the incidence of MDRO-colonization in HCC patients and to evaluate its impact on the clinical course.

Materials and methods

Study design and microbiological definitions

Between January 2008 and December 2017, patients with confirmed HCC presenting at the Department of Internal Medicine 1 of the Frankfurt University Hospital were included in this study. HCC was diagnosed according to current guidelines by dynamic imaging techniques with 4-phase multidetector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI) and the typical hallmark of HCC (hypervascularity in the arterial phase with washout in the portal venous or delayed phases) or by histopathological examination of biopsies taken from liver tumors or metastases (European Association for the Study of the Liver 2018).

BCLC stage, model of end-stage liver disease (MELD) score, Child–Pugh score and Albumin–Bilirubin (ALBI) grade were assessed by clinical examination, laboratory parameters and the results of ultrasound, CT scans and MRI imaging (Llovet et al. 1999; Kamath et al. 2001; Pugh et al. 1973; Johnson et al. 2015). The BCLC stage determined HCC treatment (European Association 2012). Briefly, patients with early stage HCC within the Milan criteria were either listed at Eurotransplant for liver transplantation, received resection or local ablative therapy by radiofrequency ablation (RFA). HCC patients with intermediate or advanced disease received treatment of HCC with local ablative therapy including RFA, TACE or systemic treatment as recommended by the current guidelines. Patients with end-stage HCC received best supportive care.

The study was performed in accordance with the Declaration of Helsinki. The study was approved by the institutional review board of the Frankfurt University Hospital.

Screening procedure and definitions

According to German infection law (Infektionsschutzgesetz, IfSG, initially decided in the year 2001) an infection control protocol to prevent the transmission of MDRO is
required (Bundesministerium der Justiz und für Verbraucherschutz 2019). At the University hospital Frankfurt, this legal requirement by IfSG and the recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute, Berlin, Germany were updated regularly and entirely fulfilled (Robert Koch Institut 2012). Patients reporting defined risk factors, e.g., arriving from high-prevalence countries and patients, e.g., admitted to oncology wards are systematically screened for MDRO at the day of admittance by nasal, rectal and pharyngeal swabs (Reinheimer et al. 2016, 2017).

MDRO were defined as Enterococcus faecalis or Enterococcus faecium with vancomycin resistance (VRE), Methicillin-resistant Staphylococcus aureus (MRSA) and MDRGN. MDRGN were defined as Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Proteus mirabilis with extended spectrum beta-lactamase (ESBL)-like phenotype as well as Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa resistant against piperacillin, any 3rd/4th generation Cephalosporin, and fluoroquinolones ± carbapenems. MDRGN with resistance against carbapenems have been described as Carbapenem-resistant Enterobacteriaceae (CRE) (Temkin et al. 2014).

Patients with a detection of MDRO before or within the first 90 days after diagnosis of HCC were defined as colonized HCC patients. Patients in which never a MDRO was detected were defined as noncolonized HCC patients. Patients who acquired MDRO later than 90 days after HCC diagnosis and patients that never received MDRO screening were not further investigated.

**Detection of MDRO**

For MDRO, screening culture swabs were transferred from Amies collection and transport medium onto selective agar plates for the detection of VRE, MRSA and MDRGN. Species identification was performed by Matrix-assisted laser desorption ionization–time-of-flight analysis (VITEK MS, bioMérieux, Nütringen, Germany; since the year 2011) or biochemical analysis. Antimicrobial susceptibility testing was performed according to guidelines set by Clinical and Laboratory Standards Institute (CLSI) and using VITEK 2 since the year 2010 (bioMérieux), antibiotic gradient tests or disc diffusion method.

**Statistical analysis**

This study was designed as a retrospective cohort study. All patients with diagnosed HCC were retrospectively collected from the patient’s documentation system. They were followed up until death or last contact. The primary end point was overall survival. Continuous variables are shown as means ± standard deviation and categorical variables are reported as frequencies and percentages. Differences between different patient cohorts were determined using the nonparametric Wilcoxon–Mann–Whitney and Kruskal–Wallis tests. For sub-analysis of a statistically significant Kruskal–Wallis test, the Bonferroni correction was used. P values <0.05 were considered to be significant. Predictors of survival were determined using a univariate Cox regression hazard model. Death was recorded as event. For assessment of independent predictors of survival, a multivariate Cox regression hazard model with forward stepwise (likelihood ratio) entry was used. Survival curves with the estimated hazards were calculated with the Cox regression model. Statistical analyses were performed with SPSS (Version 27.0, IBM, New York, USA) and GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA, USA).

**Results**

**Baseline characteristics and microbiological findings**

1257 patients were diagnosed with HCC between 2001 and 2017 at the University Hospital Frankfurt. HCC patients that never received MDRO screening (n = 176) and HCC patients who acquired MDRO-colonization later than 90 days after HCC diagnosis (n = 127) were excluded from further analysis (Fig. 1). For the remaining 954 HCC patients the median follow-up was 418 days (range 1–6345). 59 (6%)
were colonized with a MDRO and 895 (94%) were noncolonized (Table 1). Colonized as well as noncolonized HCC patients had a median age of 64 years (range 34–84 years and 20–89 years, respectively, \( p = 0.815 \)). The most frequently found MDRO within the 59 colonized HCC patients was ESBL/± FQ with 35 patients (59%), 19 (54.3%) of them being \( E. \) coli and 16 (45.7%) being \( K. \) pneumoniae. The second most found MDRO was VRE with 22 patients (37%) (Table 2). MRSA colonization was found in 8 HCC patients (14%), 1 patient was colonized with a CRE (2%). 6 patients (10%) were colonized with more than 1 MDRO.

### Clinical findings

Colonized HCC patients tended to have more advanced cancer disease as well as more impaired liver function (Table 3). Namely, BCLC stage D—representing end-stage HCC disease—was found in 11 colonized HCC patients (19%), but only in 42 noncolonized HCC patients (5%) \( p = 0.001 \). Analogously colonized HCC patients had more ALBI grade 3 than noncolonized HCC patients (32% vs. 9%, \( p < 0.001 \)). Colonized HCC patients had higher Child–Pugh scores than noncolonized HCC patients \( p < 0.001 \) and a higher median

### Table 1 Baseline characteristics

| Parameter                              | All patients | Colonized | Noncolonized | \( p \) Value |
|----------------------------------------|--------------|-----------|--------------|--------------|
| Epidemiology                           |              |           |              |              |
| Patients (\( n, \% \))                 | 954          | 59 (6.2)  | 895 (93.8)   |              |
| Male sex (\( n, \% \))                 | 755 (79.1)   | 41 (69.5) | 714 (79.8)   | 0.069        |
| Age (median, range)                    | 64 (20–89)   | 64 (34–84)| 64 (20–89)   | 0.815        |
| Etiology of liver disease              |              |           |              |              |
| Hepatitis B (\( n, \% \))              | 177 (18.6)   | 9 (15.3)  | 168 (18.8)   | 0.605        |
| Hepatitis C (\( n, \% \))              | 322 (33.8)   | 20 (33.9) | 301 (33.6)   | 1.0          |
| NASH (\( n, \% \))                     | 121 (12.7)   | 10 (16.9) | 111 (12.4)   | 0.421        |
| Alcohol (\( n, \% \))                  | 321 (33.7)   | 25 (42.4) | 296 (33.1)   | 0.251        |
| Cryptogenic (\( n, \% \))              | 56 (5.9)     | 5 (8.5)   | 64 (7.2)     | 0.796        |
| Other or unknown (\( n, \% \))         | 47 (4.9)     | 4 (6.8)   | 43 (4.8)     | 0.536        |

### Microbiological findings

| Character                              | Colonized |
|----------------------------------------|-----------|
| Patients (\( n, \% \))                 | 59        |
| VRE (\( n, \% \))                      | 22 (37.3) |
| Enterococcus faecalis (\( n, \% \))    | 0 (0)     |
| Entercoccus faecium (\( n, \% \))      | 22 (100)  |
| ESBL/± FQ (\( n, \% \))                | 35 (59.3) |
| Escherichia coli (\( n, \% \))         | 19 (54.3) |
| Klebsiella pneumoniae (\( n, \% \))    | 16 (45.7) |
| MRSA (\( n, \% \))                     | 8 (13.6)  |
| CRE (\( n, \% \))                      | 1 (1.7)   |
| ≥ 2 MDRO (\( n, \% \))                 | 6 (10.2)  |

| Character                              | Colonized |
|----------------------------------------|-----------|
| VRE, vancomycin-resistant Enterococcus faecalis/ faecium; ESBL/± FQ, extended-spectrum ß-lactamase phenotype with or without fluorquinolone resistance; CRE, carbapenem-resistant Enterobacterales; MRSA, methicillin-resistant S. aureus; MDRO, multidrug-resistant organism |

### Table 2 Microbiological findings

| Parameter                              | Colonized |
|----------------------------------------|-----------|
| Patients (\( n, \% \))                 | 59        |
| VRE (\( n, \% \))                      | 22 (37.3) |
| Enterococcus faecalis (\( n, \% \))    | 0 (0)     |
| Entercoccus faecium (\( n, \% \))      | 22 (100)  |
| ESBL/± FQ (\( n, \% \))                | 35 (59.3) |
| Escherichia coli (\( n, \% \))         | 19 (54.3) |
| Klebsiella pneumoniae (\( n, \% \))    | 16 (45.7) |
| MRSA (\( n, \% \))                     | 8 (13.6)  |
| CRE (\( n, \% \))                      | 1 (1.7)   |
| ≥ 2 MDRO (\( n, \% \))                 | 6 (10.2)  |

### Table 3 Clinical findings

| Parameter                              | Colonized | Noncolonized | \( p \) value |
|----------------------------------------|-----------|--------------|---------------|
| Patients (\( n, \% \))                 | 59 (6.2)  | 895 (93.8)   |               |
| BCLC stage A (\( n, \% \))             | 19 (32.2) | 469 (52.4)   | < 0.001       |
| BCLC stage B (\( n, \% \))             | 22 (37.3) | 161 (18)     | < 0.001       |
| BCLC stage C (\( n, \% \))             | 11 (18.6) | 22 (2.5)     | < 0.001       |
| MELD (median, range)                   | 14 (6–40) | 10 (6–40)    | < 0.001       |

All \( p \) values reported are two-sided. Statistical significance was defined as \( p \leq 0.05 \).

### Table 3 Clinical findings

| Parameter                              | Colonized | Noncolonized | \( p \) value |
|----------------------------------------|-----------|--------------|---------------|
| Patients (\( n, \% \))                 | 59 (6.2)  | 895 (93.8)   |               |
| BCLC stage A (\( n, \% \))             | 19 (32.2) | 469 (52.4)   | < 0.001       |
| BCLC stage B (\( n, \% \))             | 22 (37.3) | 161 (18)     | < 0.001       |
| BCLC stage C (\( n, \% \))             | 11 (18.6) | 22 (2.5)     | < 0.001       |
| MELD (median, range)                   | 14 (6–40) | 10 (6–40)    | < 0.001       |

All \( p \) values reported are two-sided. Statistical significance was defined as \( p \leq 0.05 \).
The percentage of HCC patients receiving resection (20% vs. 24%, \(p = 0.534\)), local ablation (19% vs. 21%, \(p = 0.743\)) or liver transplantation (9% vs. 10%, \(p = 1.0\)) was similar in both cohorts. Only 2 (3%) colonized HCC patients received systemic treatment with sorafenib compared to 88 (10%) of noncolonized HCC patients \((p < 0.001)\).

### Outcome

We hypothesized that MDRO-colonization might be of prognostic value in HCC patients. Therefore, the overall survival (OS) rates of colonized and noncolonized HCC patients were compared. Colonized HCC patients had a lower median OS of 189 days (6.3 months) (95% confidence interval (CI) 18–360 days) compared to a median OS of 1001 days (33.4 months) (95% CI 812–1190 days) in noncolonized HCC patients (Fig. 2). Overall, 476 HCC patients died (33 colonized and 443 noncolonized HCC patients). Regarding the causes of death in the 33 colonized HCC patients, we found 8 (24.2%) death events to be linked to infectious complications. 6 (18.2%) patients died in a setting of uncontrolled tumor disease. 4 (12.1%) HCC patients had lethal bleeding events and 3 (9.1%) patients died from acute on chronic liver failure. In 12 (38.7%) patients appropriately determining the cause of death was not possible.

To further analyze MDRO-colonization as a prognostic parameter in HCC patients a multivariate Cox regression model with forward stepwise likelihood ratio was performed. The nominal dichotome variables age above 65 years, male sex, underlying cirrhosis, Child–Pugh class C vs. A or B, BCLC stage C or D vs. A or B, ALBI grade 3 vs. grade 1 or 2, alpha-fetoprotein (AFP) > 400 ng/ml, sorafenib treatment, resection as HCC treatment and MDRO-colonization were included in this model. As shown in Table 4, in addition to the well-known risk factors in HCC, such as an advanced BCLC stage, an ALBI grade 3 or an AFP > 400 ng/ml, the colonization with an MDRO was an independent risk factor associated with a worsened overall survival.

### Discussion

Several studies have shown that MDRO-colonization adversely affects the clinical course of patients with hematological malignancies and solid tumors as well as in patients with liver disease (Ballo et al. 2019; Ferstl et al. 2017; Stratmann et al. 2020; Arvaniti et al. 2010). Although HCC is a...
leading cause of cancer-related death globally, to our knowledge this is the first study investigating the clinical impact of MDRO-colonization on patients with HCC.

Due to strict exclusion criteria (exclusion of HCC patients that never received MDRO screening and HCC patients who acquired MDRO-colonization later than 90 days after HCC diagnosis) we were able to define two clearly separated HCC patient cohorts (Fig. 1). By excluding HCC patients that were never screened for MDRO-colonization the risk of false-negative or occult positive noncolonized HCC patients was minimized. Excluded HCC patients that acquired MDRO-colonization later than 90 days after diagnosis of HCC prevented bias and confounders, as in these patients the clinical course is not primarily or at least not in the beginning determined by MDRO-colonization.

After exclusion of the above patients we found 59 (6%) of 954 HCC patients to be MDRO-colonized and 895 (94%) HCC patients to be noncolonized. The most frequent MDRO detected in colonized HCC patients was ESBL/± FQ with 59%, followed by VRE with 37%. The finding of ESBL as the most frequent MDRO in HCC patients is not surprising, since other studies analyzing the epidemiology of MDRO in Europe already described ESBL as a frequently isolated MDRO in hepatological patients (Fernandez et al. 2016b; Merli et al. 2015). A dominant prevalence of VRE-colonization was also expected. Germany has one of the highest VRE prevalence in Europe and again Hesse, North Rhine-Westphalia, Thuringia and Saxony have the highest proportion of VRE-colonization within Germany (Gastmeier et al. 2014). Surprisingly, colonization with CRE—known to cause untreatable lethal infections in patients with liver and other diseases—was only found in one HCC patients (Ballo et al. 2019; Ferstl et al. 2017).

Colonized patients with HCC had strongly impaired prognosis with a median OS of 189 days (6.3 months) compared to a median OS of 1001 days (33.4 months) in noncolonized HCC patients. The vast difference in survival for colonized and noncolonized HCC patients is due to different reasons. As shown in Table 3 cirrhosis and cancer disease were significantly more advanced in colonized HCC patients. Patients suffering from more severe cirrhosis and/or more severe HCC do often not qualify for systemic treatment and have impaired survival regardless of MDRO-colonization. They are more likely to receive antibiotic treatment, they are more often hospitalized and treated on intensive care unit and in turn more often provided with invasive devices (e.g., urinary catheter, central venous catheter etc.). All these factors impair survival and are likewise known to be risk factors for MDRO-colonization (Buul et al. 2012). Therefore, highest importance is attached to the multivariate analysis of factors associated with survival in this study. All relevant characteristics collected in our large HCC data base that potentially affect survival were included. Here, besides BCLC stage C or D, ALBI grade 3, AFP > 400 ng/ml and resection as HCC treatment, MDRO-colonization was identified as an independent prognostic factor in HCC patients. As causes for death in HCC patients vary amongst infectious complications, liver or multiple organ failure (Arroyo et al. 2020), uncontrolled tumor growth, lethal bleeding events and more (each of them possibly leading to one another), unambiguously determining the leading cause for death in HCC patients is difficult in a retrospective study setting and needs to be addressed in future prospective studies. We found, however, that only 6 (18.2%) HCC patients died in a setting of uncontrolled tumor disease. In at least 8 (24.2%) colonized HCC patients, death events were associated with infectious complications. Couto et al. showed that up to 43% of HCC patients do not die as a result of cancer progression, but from complications of the underlying cirrhosis (sepsis, bleeding etc.) (Couto et al. 2007). The fact that many HCC patients die in the absence of uncontrolled tumor growth emphasizes the importance of our finding in clinical practice even more.

At our hospital it was already reported that MDRO-colonization adversely affects survival in patients with hematological malignancies and solid tumors as well as in patients with liver disease (Ballo et al. 2019; Ferstl et al. 2017; Stratmann et al. 2020; Arvaniti et al. 2010). This is the first study proving a similar impact of MDRO-colonization on patients with HCC. Hospital antibiotic stewardship programs have shown to reduce colonization and infection with MDRO (Baur et al. 2017). Thus, clinicians should carefully balance the risks and benefits of intensive antibiotic agents to reduce incidence of MDRO colonization and infection. In summary, this study highlights the importance of MDRO screening, appropriate isolation measures as well as interdisciplinary antibiotic steward-ship programs in the context of HCC treatment, as these patients are highly susceptible to infections due to cancer and liver disease.
Declarations

Conflict of interestVera Himmelsbach: nothing to declare. Mate Knabe: nothing to declare. Philip G. Ferstl: consultancies: SNIPR Biome. Kai-Henrik Peiffer: nothing to declare. Jan A. Stratmann: nothing to declare. Thomas Wichelhaus: nothing to declare. Michael Hogardt: nothing to declare. Volkhard Kempf: nothing to declare. Stefan Zeuzem: speaker’s fees: Abbvie, Gilead, Merck/MSD, consultancy: Abbvie, Gilead, Intercept, Janssen. Oliver Waidmann: consultancies: Amgen, Bayer, BMS, Celgene, Eisai, Incyte, Ipsen, Merck Serono, MSD, Novartis, Roche, Servier, Shire; Speaker’s fees: Bayer, BMS, Celgene, Eisai, Ipsen, Novartis, Roche, Shire; Travel support: Abbvie, Bayer, BMS, Gilead, Ipsen, Merck; Grants: Basilea, Incyte, Else Kröner-Fresenius-Stiftung, Medac, Merck Serono, MSD Fabian Finkelmeier: speaker fees from Abbvie, Ipsen, Eisai, and MSD Olivier Ballo: nothing to declare.

Ethics approvalThe study was performed in accordance with the Declaration of Helsinki. The study was approved by the institutional review board of the Frankfurt University Hospital.

Consent to participatePatients provided informed written consent and patient data was provided after approval by the local Ethics Committee.

Consent for publicationPatients provided informed written consent and patient data was provided after approval by the local Ethics Committee.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Arroyo V, Moreau R, Jalan R (2020) Acute-on-chronic liver failure. N Engl J Med 382(22):2137–2145
Arvaniti V, D’Amico G, Fede G, Manousou P, Tsachatzis E, Pieguezuelo M et al (2010) Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 139(4):1246–1256
Ballo O, Tarazziti I, Stratmann J, Reinheimer C, Hogardt M, Wichelhaus TA et al (2019) Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy. PLoS ONE 14(1):e0210991
Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Dobele S et al (2017) Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 17(9):990–1001
Bundesministerium der Justiz und für Verbraucherschutz. IfSG-Gesetz zur Verhütung und Bekämpfung von Infektionskrankheiten beim Menschen; 2019 [cited 2019 Jul 22]. Available from: http://www.gesetze-im-internet.de/ifsg/BJNR104510000.html
Centers for Disease Control and Prevention (2013) Antibiotic resistance threats in the United States, 2013 (https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf).
Couto OF, Dvorich I, Carr BI (2007) Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 52(11):3285–3289
European Association for the study of the Liver European Organisation for Research and Treatment of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943
European Association for the study of the Liver (2018) Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69(1):182–236
Fernandez J, Tandon P, Mensa J, Garcia-Tsao G (2016a) Anti-biotic prophylaxis in cirrhosis: good and bad. Hepatology 63(6):2019–2031
Fernandez J, Bert F, Nicolas-Chanoine MH (2016b) The challenges of multi-drug-resistance in hepatology. J Hepatol 65(5):1043–1054
Ferstl PG, Filmann N, Brandt C, Zeuzem S, Hogardt M, Kempf VAJ et al (2017) The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease. Liver Int 37(10):1488–1496
Ferstl PG, Filmann N, Heiligenthal EM, Schnitzbauer AA, Bechstein WO, Kempf VAJ et al (2021) Colonization with multidrug-resistant organisms is associated with increased mortality in liver transplant candidates. PLoS ONE 16(1):e0245091
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905
Gastmeier P, Schroder C, Behnek M, Meyer E, Geffers C (2014) Dramatic increase in vancomycin-resistant enterococci in Germany. J Antimicrob Chemother 69(6):1660–1664
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol 33(6):550–558
Kamath PS, Wiesner RH, Maldonado M, Kremers W, Therneau TM, Kosberg CL et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33(2):464–470
Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329–338
Merli M, Lucidi C, Di Gregorio V, Falcone M, Giannelli V, Lattanzi B et al (2015) The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective study. PLoS ONE 10(5):e0127448
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649
Reinheimer C, Kempf VA, Gottig S, Hogardt M, Wichelhaus TA, O’Rourke F et al (2016) (2016) Multidrug-resistant organisms detected in refugee patients admitted to a University Hospital, Germany June December 2015. Euro Surveill 21(2):30110
Reinheimer C, Kempf VA, Jozsa K, Wichelhaus TA, Hogardt M, O’Rourke F et al (2017) Prevalence of multidrug-resistant organisms in refugee patients, medical tourists and domestic patients admitted to a German university hospital. BMC Infect Dis 17(1):17
Robert Koch Institut (2012) Hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gram-negativen Stäbchen. Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (RKI), Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55(10):1311–1354.
Stratmann JA, Lacko R, Ballo O, Shaid S, Gleiber W, Vehreschild M et al (2020) Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer. PLoS ONE 15(11):e0242544
Temkin E, Adler A, Lerner A, Carmeli Y (2014) Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci 1323:22–42
van Buul LW, van der Steen JT, Veenhuizen RB, Achterberg WP, Schellevis FG, Essink RT et al (2012) Antibiotic use and resistance in long term care facilities. J Am Med Dir Assoc 13(6):568 e1–13
Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 380(15):1450–1462

Waidmann O, Kempf VA, Brandt C, Zeuzem S, Piiper A, Kronenberger B (2015) Colonisation with multidrug-resistant bacteria is associated with increased mortality in patients with cirrhosis. Gut 64(7):1183–1184

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.